391 related articles for article (PubMed ID: 25911312)
21. Prognostic value of computed tomography texture features in non-small cell lung cancers treated with definitive concomitant chemoradiotherapy.
Ahn SY; Park CM; Park SJ; Kim HJ; Song C; Lee SM; McAdams HP; Goo JM
Invest Radiol; 2015 Oct; 50(10):719-25. PubMed ID: 26020832
[TBL] [Abstract][Full Text] [Related]
22. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
23. Dipyridamole modulated Tc-99m sestamibi lung SPECT in small cell lung cancer.
Bom HS; Lim SC; Kim YC; Song HC; Min JJ; Jeong HJ; Kim JY; Lee J; Park KO
Clin Nucl Med; 1999 Feb; 24(2):97-101. PubMed ID: 9988065
[TBL] [Abstract][Full Text] [Related]
24. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.
Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J
PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376
[TBL] [Abstract][Full Text] [Related]
25. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B
J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
[TBL] [Abstract][Full Text] [Related]
26. Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria.
Lee HY; Lee KS; Hwang HS; Lee JW; Ahn MJ; Park K; Kim TS; Yi CA; Chung MJ
Korean J Radiol; 2010; 11(6):618-26. PubMed ID: 21076587
[TBL] [Abstract][Full Text] [Related]
27. The usefulness of 99mTc-tetrofosmin SPECT in monitoring the response to chemotherapy in lung cancer patients.
Spanu A; Ginesu F; Pirina P; Schillaci O; Farris A; Chessa F; Madeddu G; Falchi A; Madeddu G
Oncol Rep; 2003; 10(6):1701-7. PubMed ID: 14534682
[TBL] [Abstract][Full Text] [Related]
28. The role of Tc-99m sestamibi imaging in predicting clinical response to chemotherapy in lung cancer.
Dirlik A; Burak Z; Goksel T; Erinc R; Karakus H; Ozcan Z; Veral A; Ozhan M
Ann Nucl Med; 2002 Apr; 16(2):103-8. PubMed ID: 12043903
[TBL] [Abstract][Full Text] [Related]
29. Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
Novello S; Vavalà T; Levra MG; Solitro F; Pelosi E; Veltri A; Scagliotti GV
Clin Lung Cancer; 2013 May; 14(3):230-7. PubMed ID: 23276821
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer.
Mac Manus MP; Hicks RJ; Matthews JP; McKenzie A; Rischin D; Salminen EK; Ball DL
J Clin Oncol; 2003 Apr; 21(7):1285-92. PubMed ID: 12663716
[TBL] [Abstract][Full Text] [Related]
31. The role of Tc-99m (V) DMSA scintigraphy in the diagnosis and follow-up of lung cancer lesions.
Ergün EL; Kara PO; Gedik GK; Kars A; Türker A; Caner B
Ann Nucl Med; 2007 Jul; 21(5):275-83. PubMed ID: 17634845
[TBL] [Abstract][Full Text] [Related]
32. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival.
Jeong JU; Chung WK; Nam TK; Song JY; Yoon MS; Kim YC; Kim KS; Oh IJ; Ban HJ; Kwon SY; Bom HS; Ahn SJ
Anticancer Res; 2014 May; 34(5):2517-23. PubMed ID: 24778069
[TBL] [Abstract][Full Text] [Related]
33. Tc-99m MIBI SPECT in prediction of prognosis in patients with small cell lung cancer.
Akgun A; Cok G; Karapolat I; Goksel T; Burak Z
Ann Nucl Med; 2006 May; 20(4):269-75. PubMed ID: 16856570
[TBL] [Abstract][Full Text] [Related]
34. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
Yüksel M; Cermik TF; Doğanay L; Karlikaya C; Cakir E; Salan A; Berkarda S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):876-81. PubMed ID: 12111127
[TBL] [Abstract][Full Text] [Related]
35. (99m)Tc-DTPA dynamic SPECT and CT volumetry for measuring split renal function in live kidney donors.
Miyazaki C; Harada H; Shuke N; Okizaki A; Miura M; Hirano T
Ann Nucl Med; 2010 Apr; 24(3):189-95. PubMed ID: 20213340
[TBL] [Abstract][Full Text] [Related]
36. Tumor angiogenesis at baseline identified by
Wei Y; Qin X; Liu X; Zheng J; Luan X; Zhou Y; Yu J; Yuan S
J Transl Med; 2022 Feb; 20(1):63. PubMed ID: 35109866
[TBL] [Abstract][Full Text] [Related]
37. Loss of lung function after chemo-radiotherapy for NSCLC measured by perfusion SPECT/CT: Correlation with radiation dose and clinical morbidity.
Farr KP; Møller DS; Khalil AA; Kramer S; Morsing A; Grau C
Acta Oncol; 2015; 54(9):1350-4. PubMed ID: 26203930
[TBL] [Abstract][Full Text] [Related]
38. Does response to induction chemotherapy predict survival for locally advanced non-small-cell lung cancer? Secondary analysis of RTOG 8804/8808.
McAleer MF; Moughan J; Byhardt RW; Cox JD; Sause WT; Komaki R
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):802-8. PubMed ID: 19540055
[TBL] [Abstract][Full Text] [Related]
39. Chemical Exchange Saturation Transfer MRI: Capability for Predicting Therapeutic Effect of Chemoradiotherapy on Non-Small Cell Lung Cancer Patients.
Ohno Y; Yui M; Yamamoto K; Takenaka D; Koyama H; Nagata H; Ueda T; Ikeda H; Ozawa Y; Toyama H; Yoshikawa T
J Magn Reson Imaging; 2023 Jul; 58(1):174-186. PubMed ID: 36971493
[TBL] [Abstract][Full Text] [Related]
40. [Prognostic value of 9mTc-HL91 SPECT hypoxia imaging in patients with advanced NSCLC].
Li L; Yu JM; Sun XD; Zhu H; Yue JB; Sun CJ; Yang GR
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):127-30. PubMed ID: 17645850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
